Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

KOS-1584 is in Phase 1 clinical trials in patients with solid tumors.

Kosan's motilin agonist, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD).

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements related to the further development and potential safety, efficacy, commercialization and other characteristics of tanespimycin and Kosan's development plans with respect to tanespimycin, including but not limited to Kosan's plans for the TIME registration program. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of tanespimycin, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

Revlimid(R) (lenalidomide) is a registered trademark of Celgene Corporation

Cremophor(R) is a registered trademark of BASF Corporation


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Arbor Pharmaceuticals, LLC. - ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product ... the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Arbor Pharmaceuticals, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds ... Brazil , Russia ... China (BRIC) will see robust expansion as ... favored over surgical procedures. Although revenues will be somewhat ... challenges, prolonged device approval times and demand for low-cost ...
(Date:9/30/2014)... , Sept. 30, 2014  According to their ... of cancer clinical trials is going through a ... and the work of the current clinical trial ... of ,next generation, clinical trials, which will ultimately ... The company has been recognized by ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... NEW YORK, Jan. 16, 2012 Reportlinker.com ... is available in its catalogue: ... Medical Devices to 2016 ... gives a thorough analysis of the refurbished ...
... Conn., Jan. 13, 2012 /PRNewswire-iReach/ -- Global Information, ... report, "Insulin Delivery Devices - Global Pipeline Analysis, Competitive Landscape ... http://photos.prnewswire.com/prnh/20120113/CG35865 ) The Insulin Delivery ... 6% to Reach $11 Billion by 2017 ...
Cached Medicine Technology:The Market Outlook for Refurbished Medical Devices to 2016 2The Market Outlook for Refurbished Medical Devices to 2016 3The Market Outlook for Refurbished Medical Devices to 2016 4Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 2Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 3Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 4
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... finding from Duke Medicine suggests that some people who ... be hard-wired to gain weight when exposed to chronic ... estimated 13 percent of people, all of whom are ... could help them reduce heart disease with simple interventions ... , "Genetic susceptibility, psychosocial stress and metabolic factors act ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Between 23 ... in the U.S., according to figures from the National ... Diseases Association (AARDA), and many of them have something ... of having undiagnosed celiac disease. Gluten Free Therapeutics, ... awareness of undiagnosed celiac disease by publishing a series ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... be releasing both Raima Database Manager (RDM) products ... version 9.1 and RDM Server will be released ... RDM,s high availability by providing replication between RDM ... provide developers of embedded systems with an easy ...
... shortened course of radiation therapy for prostate cancer ... PSA response for early-stage prostate cancer and has ... to a March 15 study in the ... journal of the American Society for Radiation Oncology ...
... and getaway destinations are affected, studies find , , SUNDAY, March ... allergies can be a burden on a family,s finances and ... to be presented in Washington, D.C., at the annual meeting ... how these common conditions can have a wide impact on ...
... Manufacturers Association issued the following statement from its president ... to President Obama,s nomination of Dr. Margaret Hamburg as ... (FDA), his nomination of Dr. Joshua Sharfstein as Principal ... a White House Food Safety Working Group:"We applaud President ...
... have exams, even if they have problems, study finds, , , ... coverage, or no health care coverage, are less likely to ... according to a new study. , The finding stems from ... part in the National Health Interview Survey from 1997 through ...
... in health care recruiting and staffing. Individuals have the choice of ... working with an established Health Career Agents office. , ... ... Agents now has three ways for qualified individuals to get involved ...
Cached Medicine News:Health News:Birdstep Technology Announces The Dual Upcoming Release Of Its Raima Database Manager Products 2Health News:Birdstep Technology Announces The Dual Upcoming Release Of Its Raima Database Manager Products 3Health News:Early results favorable for 5-day radiation treatment of early stage prostate cancer 2Health News:Child's Food Allergies Take Toll on Family Plans 2Health News:Grocery Manufacturers Association Statement Regarding President Obama's Nomination of FDA Commissioner 2Health News:Eye Care Checkups Tied to Insurance Status 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: